Therapy for fungal infections in leukemia.

R. E. Segal, Grace Y. Minamoto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Invasive fungal infections remain a common cause of morbidity and mortality among patients with leukemia who become further compromised by neutropenia. Candida and Aspergillus spp account for the vast majority of these infections, but other, less commonly recognized fungi can cause life-threatening infection in these hosts as well. The earlier, more limited antifungal armamentarium of ketoconazole, flucytosine, and amphotericin B has been substantially augmented by the availability of fluconazole, itraconazole, and the lipid-associated amphotericin formulations. Intense clinical study has focused on the use of these agents in empiric treatment, treatment of suspected or proven infection, and prophylaxis. Recognition of the limitations of antifungal therapy in the neutropenic host has led to evaluation of the adjunctive role of immunotherapy.

Original languageEnglish (US)
Pages (from-to)201-208
Number of pages8
JournalCurrent Oncology Reports
Volume3
Issue number3
StatePublished - May 2001

Fingerprint

Mycoses
Leukemia
Amphotericin B
Infection
Flucytosine
Ketoconazole
Itraconazole
Fluconazole
Aspergillus
Neutropenia
Candida
Immunotherapy
Fungi
Therapeutics
Morbidity
Lipids
Mortality

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Therapy for fungal infections in leukemia. / Segal, R. E.; Minamoto, Grace Y.

In: Current Oncology Reports, Vol. 3, No. 3, 05.2001, p. 201-208.

Research output: Contribution to journalArticle

@article{9853e15320474f7c92572b108240ed14,
title = "Therapy for fungal infections in leukemia.",
abstract = "Invasive fungal infections remain a common cause of morbidity and mortality among patients with leukemia who become further compromised by neutropenia. Candida and Aspergillus spp account for the vast majority of these infections, but other, less commonly recognized fungi can cause life-threatening infection in these hosts as well. The earlier, more limited antifungal armamentarium of ketoconazole, flucytosine, and amphotericin B has been substantially augmented by the availability of fluconazole, itraconazole, and the lipid-associated amphotericin formulations. Intense clinical study has focused on the use of these agents in empiric treatment, treatment of suspected or proven infection, and prophylaxis. Recognition of the limitations of antifungal therapy in the neutropenic host has led to evaluation of the adjunctive role of immunotherapy.",
author = "Segal, {R. E.} and Minamoto, {Grace Y.}",
year = "2001",
month = "5",
language = "English (US)",
volume = "3",
pages = "201--208",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Therapy for fungal infections in leukemia.

AU - Segal, R. E.

AU - Minamoto, Grace Y.

PY - 2001/5

Y1 - 2001/5

N2 - Invasive fungal infections remain a common cause of morbidity and mortality among patients with leukemia who become further compromised by neutropenia. Candida and Aspergillus spp account for the vast majority of these infections, but other, less commonly recognized fungi can cause life-threatening infection in these hosts as well. The earlier, more limited antifungal armamentarium of ketoconazole, flucytosine, and amphotericin B has been substantially augmented by the availability of fluconazole, itraconazole, and the lipid-associated amphotericin formulations. Intense clinical study has focused on the use of these agents in empiric treatment, treatment of suspected or proven infection, and prophylaxis. Recognition of the limitations of antifungal therapy in the neutropenic host has led to evaluation of the adjunctive role of immunotherapy.

AB - Invasive fungal infections remain a common cause of morbidity and mortality among patients with leukemia who become further compromised by neutropenia. Candida and Aspergillus spp account for the vast majority of these infections, but other, less commonly recognized fungi can cause life-threatening infection in these hosts as well. The earlier, more limited antifungal armamentarium of ketoconazole, flucytosine, and amphotericin B has been substantially augmented by the availability of fluconazole, itraconazole, and the lipid-associated amphotericin formulations. Intense clinical study has focused on the use of these agents in empiric treatment, treatment of suspected or proven infection, and prophylaxis. Recognition of the limitations of antifungal therapy in the neutropenic host has led to evaluation of the adjunctive role of immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0035350127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035350127&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 201

EP - 208

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 3

ER -